Inhibrx, Inc. (INBX) Stock Forecast
INBX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 4 analysts
- Price target
- $266.67 average of analyst targets
- Upside to target
- +196.9% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-2.50
- 52-week range
- $28.36 – $141.84
INBX analyst ratings
4 analystsNumber of analysts at each rating.
INBX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
INBX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.35 | −$2.57 | −$2.14 | −$2.28 | −3.3% | 2 |
| Current fiscal year (2026) | −$9.26 | −$9.58 | −$8.93 | −$9.04 | −2.4% | 2 |
| Next fiscal year (2027) | −$8.76 | −$9.05 | −$8.47 | −$9.26 | +5.3% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
INBX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 3 |
| Next fiscal year (2027) | $36.1M | $23.9M | $54.0M | 0.0% | 3 |
INBX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
INBX revenue: reported and forecast
INBX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.39 | −$2.39 | −$2.39 | −$2.35 | −$2.35 | −1.5% | 0 up · 1 down |
| Current fiscal year (2026) | −$9.26 | −$9.26 | −$9.26 | −$9.26 | −$9.26 | −0.1% | 0 up · 1 down |
| Next fiscal year (2027) | −$6.30 | −$6.30 | −$6.30 | −$8.76 | −$8.76 | +39.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
INBX earnings surprises
Reported EPS vs the consensus estimate for the last 10 quarters; INBX beat in 5 of 10.
What analysts expect from INBX
4 analysts cover Inhibrx; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $266.67, 196.9% above the latest close of $89.83. Analysts expect earnings of −$9.26 per share for 2026, −2.4% from a year earlier. For 2027 the average estimate is −$8.76 per share on revenue of $36.1 million. Inhibrx beat the EPS estimate in 5 of the last 10 quarters.
Related: INBX income statement, INBX key metrics, INBX chart. See the INBX stock overview for the latest quote and news.
INBX forecast FAQ
What is Inhibrx's price target?
The average analyst price target for Inhibrx is $266.67, 196.9% above the latest close of $89.83.
Is Inhibrx a buy, hold or sell?
Of 4 analysts covering Inhibrx, 3 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Inhibrx's EPS forecast?
Analysts forecast −$9.26 per share for 2026 (range −$9.58 to −$8.93); for 2027 the estimate is −$8.76.
When does Inhibrx report earnings?
Inhibrx is expected to report results for the quarter ending September 30, 2026 on November 13, 2026 after the market closes; the EPS estimate is $-2.50.
Does Inhibrx usually beat earnings estimates?
Inhibrx reported EPS at or above the analyst estimate in 5 of the last 10 quarters.